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Oral administration of Lactobacillus casei Shirota can ameliorate the adverse effect of 
an acute aflatoxin exposure in sprague dawley rats 
 
ABSTRACT 
Aflatoxin B₁(AFB₁) is a toxic compound commonly found in some crops with an adverse health 
effect on human and animals. Some beneficial microorganisms (or probiotics) such as lactic 
acid bacteria have shown the ability to reduce the bioavailability of aflatoxins and its intestinal 
absorption. However, the dose and duration of aflatoxins exposure and probiotic treatment can 
influence the ability of probiotics to remove aflatoxins. Therefore, this research aimed to 
investigate the efficacy of oral probiotic Lactobacillus casei Shirota strain (LcS) induction in 
an acute exposure to AFB₁ in rats. Experimentally, Sprague Dawley rats were divided into 
three groups: AFB₁ only (n = 9); AFB₁ treated with LcS (n = 9); and control (no AFB₁ exposure) 
(n = 6) groups. The blood AFB₁ level of rats treated with LcS was slightly lower than the 
untreated AFB₁ induced rats (11.12 ± 0.71 vs 10.93 ± 0.69 ng g-1). Also, LcS treatment slightly 
moderated the liver and kidney biomarkers in AFB₁ induced rats. However, a trend for a 
significant difference was only observed in ALT of AFB₁ induced rats treated with LcS 
compared to their counterparts (126.11 ± 36.90 vs 157.36 ± 15.46, p = 0.06). Rats' body weight 
decreased in all animals force-fed with AFB₁ with no significant difference between LcS 
treatment compared to the counterpart. In conclusion, this experiment indicated that probiotic 
LsC was able to slightly ameliorate the adverse effect of an acute exposure to AFB₁ in rats. 
However, future studies with longer probiotics treatment or higher probiotics dose is required 
to confirm these findings.  
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